{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:50:54Z","timestamp":1773471054007,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,30]]},"DOI":"10.7759\/cureus.42704","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T05:03:50Z","timestamp":1690779830000},"source":"Crossref","is-referenced-by-count":1,"title":["Tumor Necrosis Factor-Alpha (+489 G\/A) Polymorphism Can Predict the Response to Adalimumab in Chinese Han Patients With Ankylosing Spondylitis"],"prefix":"10.7759","author":[{"given":"Hong-Jin","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Cai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Hua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-duo","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun J","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007, 369:1379-90. 10.1016\/S0140-6736(07)60635-7","journal-title":"Lancet"},{"key":"ref2","article-title":"Ankylosing spondylitis in Shantou, China: 15 years' clinical experience","volume":"30","author":"Zeng QY","year":"2003","unstructured":"Zeng QY. Ankylosing spondylitis in Shantou, China: 15 years' clinical experience. J Rheumatol. 2003, 30:1816-21.","journal-title":"J Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468.pub2","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","author":"Maxwell LJ","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A, et al.. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015, CD005468. 10.1002\/14651858.CD005468.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang F","year":"2014","unstructured":"Huang F, Gu J, Zhu P, et al.. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis. 2014, 73:587-94. 10.1136\/annrheumdis-2012-202533","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2012.53","article-title":"Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases","volume":"13","author":"Prieto-P\u00e9rez R","year":"2013","unstructured":"Prieto-P\u00e9rez R, Cabaleiro T, Daud\u00e9n E, Abad-Santos F. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J. 2013, 13:297-305. 10.1038\/tpj.2012.53","journal-title":"Pharmacogenomics J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden S","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984, 27:361-8. 10.1002\/art.1780270401","journal-title":"Arthritis Rheum"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper J","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, et al.. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009, 68:ii1-44. 10.1136\/ard.2008.104018","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado P","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011, 70:47-53. 10.1136\/ard.2010.138594","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro S","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al.. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023, 82:19-34. 10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/art.41042","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward MM","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al.. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019, 71:1599-613. 10.1002\/art.41042","journal-title":"Arthritis Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13510","article-title":"2018 APLAR axial spondyloarthritis treatment recommendations","volume":"22","author":"Tam LS","year":"2019","unstructured":"Tam LS, Wei JC, Aggarwal A, et al.. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019, 22:340-56. 10.1111\/1756-185X.13510","journal-title":"Int J Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen JS","year":"2018","unstructured":"Smolen JS, Sch\u00f6ls M, Braun J, et al.. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018, 77:3-17. 10.1136\/annrheumdis-2017-211734","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6661281","article-title":"Correlation between TNF-\u03b1 -308 and +489 gene polymorphism and acute exacerbation of chronic obstructive pulmonary diseases","volume":"2021","author":"Yu S","year":"2021","unstructured":"Yu S, Xue M, Yan Z, Song B, Hong H, Gao X. Correlation between TNF-\u03b1 -308 and +489 gene polymorphism and acute exacerbation of chronic obstructive pulmonary diseases. Biomed Res Int. 2021, 2021:6661281. 10.1155\/2021\/6661281","journal-title":"Biomed Res Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363632","article-title":"Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis","volume":"1","author":"van Krugten MV","year":"1999","unstructured":"van Krugten MV, Huizinga TW, Kaijzel EL, et al.. Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes Immun. 1999, 1:91-6. 10.1038\/sj.gene.6363632","journal-title":"Genes Immun"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.123","article-title":"TNF-\u03b1 gene polymorphisms: association with disease susceptibility and response to anti-TNF-\u03b1 treatment in psoriatic arthritis","volume":"134","author":"Murdaca G","year":"2014","unstructured":"Murdaca G, Gulli R, Span\u00f2 F, et al.. TNF-\u03b1 gene polymorphisms: association with disease susceptibility and response to anti-TNF-\u03b1 treatment in psoriatic arthritis. J Invest Dermatol. 2014, 134:2503-9. 10.1038\/jid.2014.123","journal-title":"J Invest Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel175","article-title":"The -308 tumour necrosis factor-\u03b1 gene polymorphism predicts therapeutic response to TNF\u03b1-blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"46","author":"Seitz M","year":"2007","unstructured":"Seitz M, Wirthm\u00fcller U, M\u00f6ller B, Villiger PM. The -308 tumour necrosis factor-\u03b1 gene polymorphism predicts therapeutic response to TNF\u03b1-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007, 46:93-6. 10.1093\/rheumatology\/kel175","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.133","article-title":"TNF-\u03b1 -857 and -1031 polymorphisms predict good therapeutic response to TNF-\u03b1 blockers in Chinese Han patients with ankylosing spondylitis","volume":"13","author":"Tong Q","year":"2012","unstructured":"Tong Q, Zhao DB, Bajracharya P, et al.. TNF-\u03b1 -857 and -1031 polymorphisms predict good therapeutic response to TNF-\u03b1 blockers in Chinese Han patients with ankylosing spondylitis. Pharmacogenomics. 2012, 13:1459-67. 10.2217\/pgs.12.133","journal-title":"Pharmacogenomics"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2015.49","article-title":"The -308 TNF\u03b1 and the -174 IL-6 promoter polymorphisms associate with effective anti-TNF\u03b1 treatment in seronegative spondyloarthritis","volume":"16","author":"Fabris M","year":"2016","unstructured":"Fabris M, Quartuccio L, Fabro C, et al.. The -308 TNF\u03b1 and the -174 IL-6 promoter polymorphisms associate with effective anti-TNF\u03b1 treatment in seronegative spondyloarthritis. Pharmacogenomics J. 2016, 16:238-42. 10.1038\/tpj.2015.49","journal-title":"Pharmacogenomics J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/srep32202","article-title":"Tnf-\u03b1 promoter polymorphisms predict the response to etanercept more powerfully than that to infliximab\/adalimumab in spondyloarthritis","volume":"6","author":"Liu J","year":"2016","unstructured":"Liu J, Dong Z, Zhu Q, et al.. Tnf-\u03b1 promoter polymorphisms predict the response to etanercept more powerfully than that to infliximab\/adalimumab in spondyloarthritis. Sci Rep. 2016, 6:32202. 10.1038\/srep32202","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh550","article-title":"The influence of a polymorphism at position \u2212857 of the tumour necrosis factor \u03b1 gene on clinical response to etanercept therapy in rheumatoid arthritis","volume":"44","author":"Kang CP","year":"2005","unstructured":"Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position \u2212857 of the tumour necrosis factor \u03b1 gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005, 44:547-52. 10.1093\/rheumatology\/keh550","journal-title":"Rheumatology (Oxford)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg B","year":"2010","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010, 69:2002-8. 10.1136\/ard.2009.124446","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/171772-tumor-necrosis-factor-alpha-489-ga-polymorphism-can-predict-the-response-to-adalimumab-in-chinese-han-patients-with-ankylosing-spondylitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:06Z","timestamp":1707508986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/171772-tumor-necrosis-factor-alpha-489-ga-polymorphism-can-predict-the-response-to-adalimumab-in-chinese-han-patients-with-ankylosing-spondylitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.42704","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,30]]}}}